NASDAQ:BJDX Bluejay Diagnostics (BJDX) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free BJDX Stock Alerts $0.64 +0.09 (+16.31%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.57▼$0.6750-Day Range$0.55▼$0.9052-Week Range$0.47▼$13.98Volume634,979 shsAverage Volume54,026 shsMarket Capitalization$1.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Bluejay Diagnostics alerts: Email Address Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Bluejay Diagnostics Stock (NASDAQ:BJDX)Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Read More BJDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BJDX Stock News HeadlinesApril 23, 2024 | americanbankingnews.comBluejay Diagnostics (NASDAQ:BJDX) Trading Up 12.7%April 9, 2024 | finance.yahoo.comBJDX: 2023 Financial UpdateApril 27, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 29, 2024 | msn.comBJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023January 2, 2024 | finance.yahoo.comBluejay Diagnostics Announces Closing of $3.5 Million Public OfferingDecember 28, 2023 | marketwatch.comBluejay Diagnostics Shares Slide Premarket After Stock OfferingDecember 28, 2023 | msn.comWhy BlueJay Diagnostics Stock Is FallingDecember 28, 2023 | markets.businessinsider.comBluejay Diagnostics Prices Offering Of 2.692 Mln Shares At $1.30/shrApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.December 28, 2023 | msn.comBJDX: SYMON Says: Start the Trial! - MSNDecember 28, 2023 | finance.yahoo.comBJDX: SYMON Says: Start the Trial!December 28, 2023 | finance.yahoo.comBluejay Diagnostics Announces Pricing of $3.5 Million Public OfferingNovember 21, 2023 | msn.comBluejay Diagnostics files to sell common stocks, warrantsNovember 10, 2023 | msn.comBluejay Diagnostics GAAP EPS of -$2.08November 9, 2023 | finance.yahoo.comBluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 | finance.yahoo.comBJDX: Toray License RenegotiationOctober 21, 2023 | health.usnews.comBlue adVantage Premier (PPO)October 21, 2023 | health.usnews.comTrue Blue Special Needs Plan (HMO D-SNP)September 20, 2023 | benzinga.comWhat's Going On With Bluejay Diagnostics Stock Today?August 28, 2023 | finance.yahoo.comBJDX: FDA Meeting Confirms PathwayAugust 16, 2023 | finanznachrichten.deBluejay Diagnostics, Inc.: Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial ResultsAugust 16, 2023 | finance.yahoo.comBluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finance.yahoo.comBluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price RequirementAugust 3, 2023 | msn.comDawson James Downgrades Bluejay Diagnostics (BJDX)August 3, 2023 | msn.comBluejay Diagnostics (BJDX) Price Target Increased by 1900.00% to 61.20July 28, 2023 | benzinga.comWhat's Going On With BlueJay Diagnostics Stock?July 24, 2023 | marketwatch.comBluejay Diagnostics Shares Rise 82% After Reverse Stock SplitSee More Headlines Receive BJDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/27/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:BJDX CUSIPN/A CIK1704287 Webwww.bluejaydx.com Phone844-327-7078FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-168.38% Return on Assets-122.58% Debt Debt-to-Equity RatioN/A Current Ratio1.82 Quick Ratio1.82 Sales & Book Value Annual Sales$250,000.00 Price / Sales6.91 Cash FlowN/A Price / Cash FlowN/A Book Value$2.34 per share Price / Book0.27Miscellaneous Outstanding Shares2,690,000Free Float1,425,000Market Cap$1.73 million OptionableNot Optionable Beta0.85 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Indranil Dey (Age 60)Principal Financial, Accounting & Executive Officer, President, CEO and Director Comp: $413.16kDr. Jason Cook (Age 41)Chief Technology Officer Comp: $278.42kMr. Les DeLucaVice President of OperationsEryn GrahamMarketing ManagerMr. Kevin Vance (Age 66)Chief Commercial Officer Mark W. FeinbergChief Medical AdvisorDr. Mark W. Feinberg M.D.Chief Medical AdvisorRyan McSeveneyCorporate ControllerMore ExecutivesKey CompetitorsReShape LifesciencesNASDAQ:RSLSQuoin PharmaceuticalsNASDAQ:QNRXSintx TechnologiesNASDAQ:SINTDynatronicsNASDAQ:DYNTTenon MedicalNASDAQ:TNONView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 24,230 shares on 2/13/2024Ownership: 1.954%View All Institutional Transactions BJDX Stock Analysis - Frequently Asked Questions Should I buy or sell Bluejay Diagnostics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bluejay Diagnostics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BJDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BJDX, but not buy additional shares or sell existing shares. View BJDX analyst ratings or view top-rated stocks. How have BJDX shares performed in 2024? Bluejay Diagnostics' stock was trading at $1.22 at the start of the year. Since then, BJDX shares have decreased by 47.4% and is now trading at $0.6419. View the best growth stocks for 2024 here. Are investors shorting Bluejay Diagnostics? Bluejay Diagnostics saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 400 shares, a decline of 96.4% from the March 31st total of 11,000 shares. Based on an average daily volume of 40,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short. View Bluejay Diagnostics' Short Interest. When is Bluejay Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BJDX earnings forecast. How were Bluejay Diagnostics' earnings last quarter? Bluejay Diagnostics, Inc. (NASDAQ:BJDX) issued its quarterly earnings data on Thursday, March, 28th. The company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $1.10. When did Bluejay Diagnostics' stock split? Bluejay Diagnostics shares reverse split on Monday, July 24th 2023. The 1-20 reverse split was announced on Monday, July 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Bluejay Diagnostics IPO? Bluejay Diagnostics (BJDX) raised $22 million in an IPO on Wednesday, November 10th 2021. The company issued 2,160,000 shares at a price of $10.00 per share. How do I buy shares of Bluejay Diagnostics? Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BJDX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
